HK1146484A1 - Thiazolidinedione analogues for the treatment of hypertension - Google Patents
Thiazolidinedione analogues for the treatment of hypertensionInfo
- Publication number
- HK1146484A1 HK1146484A1 HK11100608.1A HK11100608A HK1146484A1 HK 1146484 A1 HK1146484 A1 HK 1146484A1 HK 11100608 A HK11100608 A HK 11100608A HK 1146484 A1 HK1146484 A1 HK 1146484A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hypertension
- treatment
- thiazolidinedione analogues
- thiazolidinedione
- analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97263907P | 2007-09-14 | 2007-09-14 | |
PCT/US2008/010723 WO2009038681A1 (fr) | 2007-09-14 | 2008-09-15 | Analogues de thiazolidinedione pour traiter l'hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1146484A1 true HK1146484A1 (en) | 2011-06-10 |
Family
ID=40239575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11100608.1A HK1146484A1 (en) | 2007-09-14 | 2011-01-21 | Thiazolidinedione analogues for the treatment of hypertension |
Country Status (16)
Country | Link |
---|---|
US (1) | US8067450B2 (fr) |
EP (1) | EP2203433B1 (fr) |
JP (1) | JP5371988B2 (fr) |
KR (1) | KR101537830B1 (fr) |
CN (1) | CN101848901B (fr) |
AU (1) | AU2008301905B2 (fr) |
BR (1) | BRPI0817096B8 (fr) |
CA (1) | CA2699289C (fr) |
ES (1) | ES2398313T3 (fr) |
HK (1) | HK1146484A1 (fr) |
IL (1) | IL204440A (fr) |
MX (1) | MX2010002820A (fr) |
NZ (2) | NZ583889A (fr) |
PL (1) | PL2203433T3 (fr) |
RU (1) | RU2486179C2 (fr) |
WO (1) | WO2009038681A1 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2646149A1 (fr) | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Analogues de thiazolidinedione |
PL2902026T3 (pl) | 2006-03-16 | 2018-03-30 | Metabolic Solutions Development Company Llc | Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie |
US8304441B2 (en) | 2007-09-14 | 2012-11-06 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic diseases |
AU2008301905B2 (en) | 2007-09-14 | 2013-06-27 | Cirius Therapeutics, Inc. | Thiazolidinedione analogues for the treatment of hypertension |
US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
WO2010105048A1 (fr) * | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Analogues de thiazolidinedione |
AU2014202074B2 (en) * | 2009-12-15 | 2016-01-07 | Cirius Therapeutics, Inc. | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
EP2512470B1 (fr) * | 2009-12-15 | 2016-11-30 | Octeta Therapeutics, LLC | Thiazolidinediones épargnant les ppar et associations pour le traitement de maladies neurodégénératives |
EP2512471A1 (fr) * | 2009-12-15 | 2012-10-24 | Metabolic Solutions Development Company LLC | Thiazolidine diones épargnant les ppar et associations pour le traitement du diabète sucré et d'autres maladies métaboliques |
CA2783262A1 (fr) * | 2009-12-15 | 2011-07-14 | Metabolic Solutions Development Company, Llc | Thiazolidine diones epargnant les ppar et associations pour le traitement de l'obesite et d'autres maladies metaboliques |
RU2564661C2 (ru) * | 2009-12-15 | 2015-10-10 | МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи | Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ |
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
ES2610623T3 (es) * | 2010-04-19 | 2017-04-28 | Octeta Therapeutics, Llc | Nueva síntesis de compuestos de tiazolidindiona |
WO2011133611A1 (fr) * | 2010-04-21 | 2011-10-27 | Metabolic Solutions Development Company | Analogues de thiazolidinedione |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2012021467A1 (fr) * | 2010-08-10 | 2012-02-16 | Metabolic Solutions Development Company, Llc | Nouvelle synthèse pour des composés de thiazolidinedione |
MX349006B (es) * | 2010-08-10 | 2017-07-06 | Cirius Therapeutics Inc | Nueva sintesis para compuestos de tiazolidindiona. |
WO2012109495A1 (fr) * | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cibles cellulaires de thiazolidinediones |
WO2012149083A1 (fr) * | 2011-04-28 | 2012-11-01 | Metabolic Solutions Development Company, Llc | Thiazolidinediones épargnant ppar pour traitement de maladies se rapportant au rein |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
WO2013068486A1 (fr) | 2011-11-08 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes pour le diagnostic et le traitement de l'infertilité masculine |
EP2968298B1 (fr) | 2013-03-14 | 2018-01-31 | Deuterx, LLC | 2,4-thiazolidinediones enrichies en deutérium et méthodes de traitement |
RU2687490C2 (ru) | 2013-07-22 | 2019-05-14 | МЕТАБОЛИК СОЛЮШИНС ДЕВЕЛОПМЕНТ КО., ЭлЭлСи | Ppar-поддерживающие соединения для лечения метаболических заболеваний |
WO2015109037A1 (fr) | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Méthodes de traitement de troubles neurologiques, métaboliques et autres à l'aide de pioglitazone énantiopure enrichie en deutérium |
US20210038566A1 (en) | 2018-02-08 | 2021-02-11 | Enyo Pharma | Use of modulators of neet proteins for the treatment of infection |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
GB202210503D0 (en) | 2022-07-18 | 2022-08-31 | Univ Court Univ Of Glasgow | Materials and methods for treatment of chronic myeloid leukemia (CML) |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
WO1986002073A1 (fr) | 1984-10-03 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant |
CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US5167228A (en) | 1987-06-26 | 1992-12-01 | Brigham And Women's Hospital | Assessment and modification of endogenous circadian phase and amplitude |
US5356913A (en) | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
WO1992018501A1 (fr) | 1991-04-11 | 1992-10-29 | The Upjohn Company | Derives de thiazolidinedione, production et utilisation desdits derives |
US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
NO302471B1 (no) * | 1991-12-26 | 1998-03-09 | Sankyo Co | Tiazolidinforbindelser og farmasöytisk preparat |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
NO305987B1 (no) * | 1994-04-11 | 1999-08-30 | Sankyo Co | Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US5798375A (en) | 1995-07-03 | 1998-08-25 | Sankyo Company, Limited | Treatment of arteriosclerosis and xanthoma |
WO2000066102A2 (fr) | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone et metformine comme inhibiteurs de formation de produits terminaux de glycation avancee (age) |
NZ530833A (en) | 1999-06-30 | 2005-08-26 | Tularik Inc | Compounds for the modulation of PPARgamma activity |
US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
RU2281285C2 (ru) | 2001-04-26 | 2006-08-10 | Зентива А.С. | Способ получения пиоглитазона в качестве противодиабетического средства |
WO2003026586A2 (fr) | 2001-09-28 | 2003-04-03 | Teva Pharmaceutical Industries Ltd. | Chlorhydrate de pioglitazone |
WO2004007490A2 (fr) | 2002-07-16 | 2004-01-22 | Cadila Healthcare Limited | Procede de preparation de pioglitazone via plusieurs intermediaires. |
EP1607103A1 (fr) * | 2003-03-20 | 2005-12-21 | Eisai Co., Ltd. | Medicament concomitant utilise comme agent therapeutique pour la maladie intestinale inflammatoire |
US7230016B2 (en) | 2003-05-13 | 2007-06-12 | Synthon Ip Inc. | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
JP2005015477A (ja) * | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
WO2005021542A2 (fr) | 2003-08-28 | 2005-03-10 | Ranbaxy Laboratories Limited | Procede pour la preparation de pioglitazone |
AR047541A1 (es) | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
ES2393197T3 (es) | 2004-09-28 | 2012-12-19 | Otsuka Pharmaceutical Co., Ltd. | Compuesto de carbostirilo |
CA2646149A1 (fr) | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Analogues de thiazolidinedione |
PL2902026T3 (pl) | 2006-03-16 | 2018-03-30 | Metabolic Solutions Development Company Llc | Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie |
JP2009530293A (ja) | 2006-03-16 | 2009-08-27 | メタボリック ソリューションズ ディベロップメント カンパニー | チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法 |
AU2008301905B2 (en) | 2007-09-14 | 2013-06-27 | Cirius Therapeutics, Inc. | Thiazolidinedione analogues for the treatment of hypertension |
WO2010105048A1 (fr) | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Analogues de thiazolidinedione |
-
2008
- 2008-09-15 AU AU2008301905A patent/AU2008301905B2/en active Active
- 2008-09-15 EP EP08832210A patent/EP2203433B1/fr active Active
- 2008-09-15 CN CN2008801147383A patent/CN101848901B/zh active Active
- 2008-09-15 MX MX2010002820A patent/MX2010002820A/es active IP Right Grant
- 2008-09-15 WO PCT/US2008/010723 patent/WO2009038681A1/fr active Application Filing
- 2008-09-15 RU RU2010114727/04A patent/RU2486179C2/ru active
- 2008-09-15 KR KR1020107008064A patent/KR101537830B1/ko active IP Right Grant
- 2008-09-15 NZ NZ583889A patent/NZ583889A/en unknown
- 2008-09-15 JP JP2010524882A patent/JP5371988B2/ja active Active
- 2008-09-15 ES ES08832210T patent/ES2398313T3/es active Active
- 2008-09-15 BR BRPI0817096A patent/BRPI0817096B8/pt active IP Right Grant
- 2008-09-15 PL PL08832210T patent/PL2203433T3/pl unknown
- 2008-09-15 US US12/677,541 patent/US8067450B2/en active Active
- 2008-09-15 NZ NZ597381A patent/NZ597381A/xx unknown
- 2008-09-15 CA CA2699289A patent/CA2699289C/fr active Active
-
2010
- 2010-03-11 IL IL204440A patent/IL204440A/en active IP Right Grant
-
2011
- 2011-01-21 HK HK11100608.1A patent/HK1146484A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ES2398313T3 (es) | 2013-03-15 |
BRPI0817096B8 (pt) | 2021-05-25 |
US8067450B2 (en) | 2011-11-29 |
KR101537830B1 (ko) | 2015-07-17 |
RU2486179C2 (ru) | 2013-06-27 |
CN101848901A (zh) | 2010-09-29 |
AU2008301905B2 (en) | 2013-06-27 |
BRPI0817096B1 (pt) | 2020-11-10 |
CN101848901B (zh) | 2012-11-21 |
CA2699289A1 (fr) | 2009-03-26 |
EP2203433B1 (fr) | 2012-10-31 |
MX2010002820A (es) | 2010-04-01 |
JP5371988B2 (ja) | 2013-12-18 |
AU2008301905A1 (en) | 2009-03-26 |
EP2203433A1 (fr) | 2010-07-07 |
BRPI0817096A2 (pt) | 2017-05-02 |
US20100222399A1 (en) | 2010-09-02 |
BRPI0817096A8 (pt) | 2017-10-10 |
CA2699289C (fr) | 2016-01-19 |
WO2009038681A1 (fr) | 2009-03-26 |
JP2010539171A (ja) | 2010-12-16 |
KR20100075915A (ko) | 2010-07-05 |
NZ583889A (en) | 2012-01-12 |
RU2010114727A (ru) | 2011-10-20 |
NZ597381A (en) | 2013-03-28 |
PL2203433T3 (pl) | 2013-04-30 |
IL204440A (en) | 2013-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1146484A1 (en) | Thiazolidinedione analogues for the treatment of hypertension | |
HK1208237A1 (en) | Methods for the treatment of gout | |
IL194076A0 (en) | Imidazolothiazole compounds for the treatment of disease | |
ZA200906129B (en) | Compounds for the treatment of hepatitis c | |
ZA200806510B (en) | Heterobicyclic sulfonamide derivatives for the treatment of diabetes | |
ZA200902374B (en) | Compositions useful for the treatment of diabetes | |
HK1206262A1 (en) | Implants for the treatment of dopamine associated states | |
SI2209784T1 (sl) | Spojine za zdravljenje hepatitisa C | |
ZA201000923B (en) | Compounds for the treatment of hepatitis c | |
IL207397A0 (en) | Difluorobiphenylamide derivtives for the treatment of ocular hypertension | |
ZA201006827B (en) | Carboxamide-heteroaryl derivatives for the treatment of diabetes | |
GB0909297D0 (en) | Composition for the treatment of skin conditions | |
GB0715790D0 (en) | Drug combination for the treatment of sialorrhoea | |
IL211189A0 (en) | Compounds for the treatment of peripheral neuropathies | |
ZA200807615B (en) | Renin inhibitors for the treatment of hypertension | |
IL193414A0 (en) | Meridamycin analogues for the treatment ofneurodegenererative disorders | |
HK1129112A1 (en) | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | |
GB0820885D0 (en) | A composition for the treatment of hypertension | |
GB0624439D0 (en) | Technique for treatment of gall-and kidney-stones | |
GB0602857D0 (en) | The treatment of sialorrhoea | |
GB0602855D0 (en) | The Treatment Of Sialorrhoea | |
GB2445888B (en) | Treatment of hypertension | |
GB0705674D0 (en) | Composition for the treatment of halitosis | |
PL1886669T3 (pl) | Preparat o działaniu immunotropowym na bazie fosfoglukanu do leczenia przerostu migdałka gardłowego | |
GB0625602D0 (en) | Treatment of sialorrhoea |